Lipocine Inc.

NasdaqCM:LPCN Stock Report

Market Cap: US$19.9m

Lipocine Management

Management criteria checks 2/4

Lipocine's CEO is Mahesh Patel, appointed in Jan 1997, has a tenure of 29.5 years. total yearly compensation is $986.34K, comprised of 59.3% salary and 40.7% bonuses, including company stock and options. directly owns 1.95% of the company’s shares, worth $387.24K. The average tenure of the management team and the board of directors is 8.7 years and 18 years respectively.

Key information

Mahesh Patel

Chief executive officer

US$986.3k

Total compensation

CEO salary percentage59.29%
CEO tenure29.5yrs
CEO ownership1.9%
Management average tenure8.7yrs
Board average tenure18yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 26

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%

Lipocine (NASDAQ:LPCN) on Monday said the company would now focus on applying its drug delivery technology to develop treatments for central nervous system (CNS) disorders. LPCN stock +4.7% to $0.52 in premarket trading. The company will use its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products, LPCN said in a statement. The initial focus for the company will be on the delivery of neuroactive steroids, which have been shown to impact CNS function. The company's CNS development portfolio includes LPCN 1154 for the treatment of postpartum depressoin, LPCN 2101 for women with epilepsy and some undisclosed candidates. LPCN said it would stop further investments in its programs for liver diseases and other disorders, and will advance them instead through partnerships. The company believes that its cash securities of $37.4M would be sufficient to support operations and capital expenditure until at least Sept. 30, 2023.
Analysis Article • Feb 22

Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 14

Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 11

When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

We feel now is a pretty good time to analyse Lipocine Inc.'s ( NASDAQ:LPCN ) business as it appears the company may be...
Analysis Article • Jan 26

Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Lipocine Inc. ( NASDAQ:LPCN ) is possibly approaching a major achievement in its business, so we would like to shine...
Analysis Article • Dec 04

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

CEO Compensation Analysis

How has Mahesh Patel's remuneration changed compared to Lipocine's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$11m

Dec 31 2025US$986kUS$585k

-US$10m

Sep 30 2025n/an/a

-US$5m

Jun 30 2025n/an/a

-US$5m

Mar 31 2025n/an/a

-US$5m

Dec 31 2024US$762kUS$565k

US$8k

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$860kUS$525k

-US$16m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$884kUS$494k

-US$11m

Sep 30 2022n/an/a

US$4m

Jun 30 2022n/an/a

US$3m

Mar 31 2022n/an/a

-US$754k

Dec 31 2021US$1mUS$471k

-US$634k

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$19m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$994kUS$457k

-US$21m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$521kUS$457k

-US$13m

Compensation vs Market: Mahesh's total compensation ($USD986.34K) is above average for companies of similar size in the US market ($USD658.00K).

Compensation vs Earnings: Mahesh's compensation has increased whilst the company is unprofitable.

CEO

Mahesh Patel (69 yo)

29.5yrs
Tenure
US$986,336
Compensation

Dr. Mahesh V. Patel, Ph D., co-founded Lipocine Inc. in 1997 and has also been its President and Chief Executive Officer since 1997 and served as its Interim Principal Financial Officer since January 31, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Mahesh Patel
Co-Founder29.5yrsUS$986.34k1.95%
$ 387.2k
Krista Fogarty
Principal Accounting Officer & Corporate Controller7.8yrsUS$445.96k0.017%
$ 3.4k
Nachiappan Chidambaram
Senior Vice President of Research & Development3.6yrsUS$530.90k0.059%
$ 11.7k
Logan Morse
Vice President of Sales9.3yrsUS$633.01kno data
Anthony DelConte
Chief Medical Director8.7yrsno datano data
8.7yrs
Average Tenure
58yo
Average Age

Experienced Management: LPCN's management team is seasoned and experienced (8.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mahesh Patel
Co-Founder29.5yrsUS$986.34k1.95%
$ 387.2k
Richard Ono
Chairman of the Board & Lead Independent Director12.5yrsUS$79.02k0.010%
$ 2.0k
Leslie Benet
Member of Scientific Advisory Boardno datano datano data
Ronald Borchardt
Member of Scientific Advisory Boardno datano datano data
George Zografi
Member of Scientific Advisory Boardno datano datano data
Tsuneji Nagai
Member of Scientific Advisory Boardno datano datano data
Alan Hofmann
Member of Scientific Advisory Boardno datano datano data
Norman Ho
Member of Scientific Advisory Boardno datano datano data
Rex Hjelm
Member of Scientific Advisory Boardno datano datano data
John Higuchi
Director23.5yrsUS$59.02k2.47%
$ 491.2k
Bradley Anderson
Member of Scientific Advisory Boardno datano datano data
Jill Jene
Independent Director4.3yrsUS$66.52k0%
$ 0
18.0yrs
Average Tenure
69yo
Average Age

Experienced Board: LPCN's board of directors are seasoned and experienced ( 18 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 11:01
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lipocine Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
John NewmanCanaccord Genuity
Corey DavisCanaccord Genuity